Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia

References

• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–1152.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013; 381:484–495.
   PubMed Web of Science ®Google Scholar
• Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29:770–775.
   PubMed Web of Science ®Google Scholar
• Chen X, Guo J, Bao J, et al. The anticancer properties of Salvia miltiorrhiza Bunge (Danshen): a systematic review. Med Res Rev. 2014;34:768–794.
   PubMed Web of Science ®Google Scholar
• Ho JH, Hong CY. Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection. J Biomed Sci. 2011;18:30.
   PubMed Web of Science ®Google Scholar
• Huang ZS, Zeng CL, Zhu LJ, et al. Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase. J Thromb Haemost. 2010; 8:1383–1393.
   PubMed Web of Science ®Google Scholar
• Yang XY, Sun L, Xu P, et al. Effects of salvianolic scid A on plantar microcirculation and peripheral nerve function in diabetic rats. Eur J Pharmacol. 2011;665:40–46.
   PubMed Web of Science ®Google Scholar
• Chen YC, Yuan TY, Zhang HF, et al. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model. Acta Pharmacol Sin. 2016;37:772–782.
   PubMed Web of Science ®Google Scholar
• Teng F, Yin Y, Cui Y, et al. Salvianolic acid A inhibits endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats. Life Sci. 2016;144:86–93.
   PubMed Web of Science ®Google Scholar
• Bi L, Chen J, Yuan X, et al. Salvianolic acid A positively regulates PTEN protein level and inhibits growth of A549 lung cancer cells. Biomed Rep. 2013;1:213–217.
   PubMedGoogle Scholar
• Kawauchi K, Ogasawara T, Yasuyama M, et al. Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med Chem. 2009;9:1024–1038.
   PubMed Web of Science ®Google Scholar
• Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17:995–997.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154–164.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yuan CY, Yuan W. Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? Stem Cell Investig. 2016;3:31.
   PubMedGoogle Scholar
• Jiang L, Xu Y, Zeng X, et al. Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma. Oncotarget. 2015;6:31191–31202.
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102:972–980.
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Lee GW, Lee JS, et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis. 2008;29:1885–1892.
   PubMed Web of Science ®Google Scholar
• Lee CY, Sher HF, Chen HW, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther. 2008;7:3527–3538.
   PubMed Web of Science ®Google Scholar
• Shin DS, Kim HN, Shin KD, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009;69:193–202.
   Google Scholar
• Wu CF, Klauck SM, Efferth T. Anticancer activity of cryptotanshinone on acute lymphoblastic leukemia cells. Arch Toxicol. 2016;90:2275–2286.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jeong SJ, Kwon TR, et al. Cryptotanshi-none enhances TNF-α-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis. 2011;16:696–707.
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen S, Yang Q, et al. Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2. Cancer Biol Ther. 2015;16:1407–1414.
   PubMed Web of Science ®Google Scholar
• Hou YY, Peng JM, Chao RB. Pharmacokinetic study of salvianolic acid A in rat after intravenous administration of Danshen injection. Biomed Chromatogr. 2007;21:598–601.
   PubMed Web of Science ®Google Scholar
• Krishna S, Low IC, Pervaiz S. Regulation of mitochondrial metabolism: yet another facet in the biology of the oncoprotein Bcl-2. Biochem J. 2011;435:545–551.
   PubMed Web of Science ®Google Scholar
• Irvine AE, McMullin MF, Ong YL. Bcl-2 family members as prognostic indicators in AML. Hematology. 2002;7:21–31.
   PubMedGoogle Scholar
• Ignatz-Hoover JJ, Wang H, Moreton SA, et al. The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia. 2015;29:918–926.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011;25:1064–1079.
   PubMed Web of Science ®Google Scholar
• Grandage VL, Gale RE, Linch DC, et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19:586–594.
   PubMed Web of Science ®Google Scholar
• Polak R, Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood. 2012;119:911–923.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027–1036.
   PubMed Web of Science ®Google Scholar
• Wiseman DH, Greystoke BF, Somervaille TC. The variety of leukemic stem cells in myeloid malignancy. Oncogene. 2014;33:3091–3098.
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–375.
   PubMed Web of Science ®Google Scholar